Teva Statement on European Commission Decision; Company to Appeal
31 Ottobre 2024 - 12:29PM
Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) is
responding to the European Decision following its
investigation into the company’s practices regarding COPAXONE® --
the standard-of-care treatment for multiple sclerosis – and
announcing its intention to appeal the judgement and fine imposed.
The company is deeply disappointed by this decision and has been
cooperating extensively with the EC since 2019. Teva disagrees with
the Commission’s legal theories which are legally untested and,
Teva believes, not supported by the facts. The company will
vigorously defend its position on appeal and is well prepared
financially to mount a defense.
Teva conducts its business lawfully and ethically and has
been a strong partner to Europe, its patients, economy and
healthcare systems. This misguided decision will not distract Teva
from its unwavering support for patients living with MS and
their families.
Media Contacts:
Kelley Dougherty (973) 832-2810
Eden Klein +972 (3) 906 2645
Grafico Azioni Teva Pharmaceutical Indu... (NYSE:TEVA)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Teva Pharmaceutical Indu... (NYSE:TEVA)
Storico
Da Dic 2023 a Dic 2024
